Lynparza (olaparib) — United Healthcare
Metastatic breast cancer
Initial criteria
- Diagnosis of metastatic or recurrent breast cancer
- Presence of deleterious or suspected deleterious germline BRCA-mutations (gBRCAm)
- One of the following: (Disease is HER2-negative AND (Disease is HR-negative OR (Disease is HR-positive AND (Disease has progressed on previous endocrine therapy OR provider attests endocrine therapy is inappropriate))) ) OR Disease is HER2-positive
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Lynparza therapy
Approval duration
12 months